Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Studie van Patritumab Deruxtecan met andere middelen tegen kanker bij deelnemers met HER2-positieve borstkanker die zich heeft verspreid en niet operatief kan worden verwijderd (MK-1022-009)

12 november 2026 bijgewerkt door: Merck Sharp & Dohme LLC

HERTHENA-Breast-01: een fase 1b/2, multicenter, open-label, dosisbepalende studie om de veiligheid en antitumoractiviteit van Patritumab Deruxtecan te evalueren bij deelnemers met HER2-positieve, inoperabele lokaal gevorderde borstkanker of gemetastaseerde borstkanker

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:

  • About the safety and how well people tolerate of patritumab deruxtecan
  • How many people have the cancer respond (get smaller or go away) to treatment

Studie Overzicht

Gedetailleerde beschrijving

The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.

Studietype

Ingrijpend

Inschrijving (Geschat)

181

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Ontario
      • Kingston, Ontario, Canada, K7L 2V7
        • Werving
        • Kingston General Hospital ( Site 0061)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 6135336541
      • Toronto, Ontario, Canada, M5G 2M9
        • Werving
        • Princess Margaret Cancer Centre ( Site 0001)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 416-946-4501
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Werving
        • Jewish General Hospital ( Site 0003)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 514-340-8222
      • Montreal, Quebec, Canada, H2X 3E4
        • Werving
        • Centre Hospitalier de l'Université de Montréal ( Site 0004)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: (514)890-8000 x20737
      • Haifa, Israël, 3109601
        • Werving
        • Rambam Health Care Campus ( Site 0011)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 04-7776234
      • Petah Tikva, Israël, 4941492
        • Werving
        • Rabin Medical Center ( Site 0012)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +972-505533121
      • Ramat Gan, Israël, 5265601
        • Werving
        • Sheba Medical Center ( Site 0010)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 03-5304498
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 467-8602
        • Werving
        • Nagoya City University Hospital ( Site 0020)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +81-52-851-5511
    • Camden
      • London, Camden, Verenigd Koninkrijk, NW1 2PG
        • Werving
        • University College London Hospital ( Site 0041)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +442034472930
    • Glasgow City
      • Glasgow, Glasgow City, Verenigd Koninkrijk, G12 0YN
        • Werving
        • The Beatson West of Scotland Cancer Centre ( Site 0043)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +441413017000
    • London, City of
      • London, London, City of, Verenigd Koninkrijk, EC1A 7BE
        • Werving
        • St Bartholomew s Hospital ( Site 0040)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +442073777000
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • University of Colorado Anschutz Medical Campus ( Site 0057)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 720-848-1030
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Werving
        • Dana-Farber Cancer Institute ( Site 0050)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 877-338-7425
    • New Jersey
      • New Brunswick, New Jersey, Verenigde Staten, 08901
        • Werving
        • Rutgers Cancer Institute of New Jersey ( Site 0052)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 732-235-2465
    • South Carolina
      • Greenville, South Carolina, Verenigde Staten, 29605
        • Werving
        • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 864-455-3600
    • Virginia
      • Fairfax, Virginia, Verenigde Staten, 22031
        • Werving
        • Inova Schar Cancer Institute ( Site 0051)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 571-472-4724
      • Seoul, Zuid -Korea, 03080
        • Werving
        • Seoul National University Hospital ( Site 0030)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 82-2-2072-0850
      • Seoul, Zuid -Korea, 05505
        • Werving
        • Asan Medical Center ( Site 0031)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +82-2-1688-7575

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention

Part 1 Arm 1:

  • Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
  • Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment

Part 1 Arm 2:

-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting

Part 1 Arm 3:

-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.

Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Uncontrolled or significant cardiovascular disease
  • Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
  • Has clinically severe respiratory compromise
  • Has any history of or evidence of any current leptomeningeal disease
  • Has clinically significant corneal disease
  • Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
  • HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Part 1: Evidence of spinal cord compression or brain metastases
  • Part 2: Evidence of spinal cord compression or brain/CNS metastases.
  • Has an active infection requiring systemic therapy
  • Concurrent active HBV and HCV infection
  • Has had major surgical procedure (excluding placement of vascular access) less than 28 days

Part1: Arm 3 ONLY

- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part 1: Patritumab deruxtecan plus trastuzumab

Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®
Experimenteel: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Experimenteel: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib

Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Tucatinib administered as oral tablets

Experimenteel: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Tijdsspanne: Up to 21 days

DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Tijdsspanne: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Tijdsspanne: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 12 months
Part 2: Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 36 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented.

Up to approximately 36 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Tijdsspanne: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 2: Duration of Response (DOR)
Tijdsspanne: Up to approximately 36 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Progression Free Survival (PFS)
Tijdsspanne: Up to approximately 36 months

PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Number of Participants with One or More AEs
Tijdsspanne: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Tijdsspanne: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Studie directeur: Medical Director, Merck Sharp & Dohme LLC

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

26 februari 2025

Primaire voltooiing (Geschat)

2 augustus 2032

Studie voltooiing (Geschat)

2 augustus 2032

Studieregistratiedata

Eerst ingediend

11 november 2024

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2024

Eerst geplaatst (Werkelijk)

13 november 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 1022-009
  • MK-1022-009 (Andere identificatie: MSD)
  • jRCT2041250022 (Register-ID: Japan Registry of Clinical Trials (jRCT))
  • 2026-528266-19 (Register-ID: EU CT)
  • U1111-1346-4321 (Register-ID: UTN)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren